OSI Pharmaceuticals has reported positive results from its Phase IIa proof-of-concept study with its dipeptidyl peptidase-IV (DPIV) inhibitor, PSN9301.

The study demonstrated that with prandial (with-meal) dosing, 14-day administration of PSN9301 reduced blood glucose levels in patients with Type 2 diabetes and was generally well-tolerated with no episodes of hypoglycemia (low blood glucose). Also presented were preclinical data on novel, orally available agonists of the G-protein coupled receptor GPR119 for the potential treatment of obesity, diabetes and associated metabolic disorders.